• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Academy of Allergy and Clinical Immunology (EAACI) 2022

July 1 - 3, 2022

  1. BENRALIZUMAB
  2. TEZEPELUMAB
  3. REAL-WORLD EVIDENCE
  4. EARLY R&D

Html

Assessment of change in food-related behaviors and anxiety in EoE and EG/EGE clinical trials using longitudinal qualitative interviews

Html

Improvements in asthma control and lung function in patients treated with benralizumab in clinical practice in Spain: ORBE II Study

Html

The efficacy of tezepelumab in patients with severe, uncontrolled asthma receiving Global Initiative for Asthma guidelines step 4 or step 5 treatment in the phase 3 NAVIGATOR study

Html

The proportions of tezepelumab-treated patients with severe, uncontrolled asthma who achieved twice the minimum clinically important difference in patient-reported outcome measures in the phase 3 NAVIGATOR study

Html

Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial aeroallergen sensitization: a pooled analysis of the phase 2b PATHWAY and phase 3 NAVIGATOR studies

Html

Disease burden and treatment pathways among patients with EoE in five European countries: evidence from real-world clinical practice

Html

REal world inVestigation of Eosinophilic-Associated disease overLap (REVEAL): healthcare resource utilization and associated cost substudy

Html

Frequency of endoscopic sinus surgery and healthcare costs in relation to comorbid asthma in subjects with CRSwNP

Html

Healthcare resource utilisation associated with intermittent oral corticosteroid use in asthma

Html

Late phase IL-13 production corresponds to the clinical late allergic response following birch pollen nasal allergen challenge

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice